Warren Buffett’s Berkshire Hathaway cuts shares in 3 drugmakers and GM

Text size

Berkshire Hathaway

reduced its holdings in three stocks of drugs—

AbbVie,

Bristol Myers Squibb,

and

Merck

– and reduced its position in

General Motors

during the second quarter, according to its 13-F file for the period released after market close on Monday.

Berkshire (ticker: BRK.A and BRK.B) increased its stake in

Kroger

(KR) and slightly reduced its stake in

Chevron

(CLC).

Overall, Berkshire CEO Warren Buffett and his investment lieutenants Todd Combs and Ted Weschler have made few noticeable changes to Berkshire’s stock portfolio.

Berkshire sold seven million shares of

General Motors (GM),

reducing its stake to 60 million shares, now worth $ 3.2 billion, while adding 10.7 million shares to its stake in Kroger, which stood at 61.8 million actions at the end of June.

Berkshire built up stakes in AbbVie (ABBV), Bristol Myers (BMY) and Merck (MRK) in 2020 and sold them in the second quarter. AbbVie’s stake fell from 2.4 million shares to 20.5 million; Bristol Myers’ stake fell by 4.7 million shares, to 26.3 million, and Merck’s position fell by almost half, falling by 8.7 million shares, to 9.2 million .

Berkshire eliminated a small stake of 643,000 shares from

Biogen

(BIIB) and slightly strengthened its position in

Aon

(AON), bringing the stake from around 300,000 shares to 4.4 million.

There has been no change at the two largest farms in Berkshire,

Apple

(AAPL) and

Bank of America

(BAC). Apple’s stake held 887 million shares worth $ 134 billion, while Bank of America’s stake was 1.01 billion shares worth $ 41 billion.

Berkshire’s stake in Chevron fell by about 600,000 shares to 23.1 million.

Write to Andrew Bary at [email protected]